Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial
Then here are some things you should know before you make the jump
WalshAM, CrispieF, KilcawleyK, OSullivanO, OSullivanMG, & ClaessonMJ (2016)
SC, Subcutaneous injection
Given that retatrutide is not yet available as an approved treatment in the UK, conversations with a healthcare professional about this medication are best framed around understanding the current evidence, exploring approved alternatives, and discussing whether participation in a clinical trial might be appropriate
Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application